0001437749-26-016543
SEC filingChallenging Q3 with 35.8% revenue decline and 71.7% gross profit drop from product headwinds, negative grants, and below-cost consumables sales, though operating loss narrowed 10.7% via expense control; cash burn continues as management manages liquidity for 12-month runway.
Revenue declined 35.8% year-over-year to $343K, primarily due to lower product revenue and negative grant revenue reflecting additional hours incurred in a re-testing phase, partially offset by increased consumables revenue. This dynamic highlights execution challenges in deploying mass spectrometry solutions for security and AgLAB applications, where product cycles remain lumpy and customer concentration poses risks during early commercialization stages. Investors should note the shift toward recurring consumables as a stabilizing factor, though topline volatility persists without broader deployment success.
Gross profit fell 71.7% to $67K, compressing the margin to 19.5% as consumables purchased at elevated COVID-period costs were sold below cost to recover value rather than incur write-offs. This deliberate strategy preserved balance sheet integrity but created a significant disconnect between revenue and profitability, underscoring the impact of historical procurement decisions on current results. Looking ahead, normalized inventory sales and pricing discipline could help restore margins, but ongoing inventory management remains critical.
Operating loss narrowed 10.7% to -$3.5M, with operating margin at -1006.7%, demonstrating effective cost controls amid revenue pressures. This progress signals management's focus on operational efficiency, even as R&D and administrative investments continue to support AgLAB 1000-D2™ development, which promises cost and time savings for hemp and cannabis processors. The improvement provides a foundation for scalability once revenue inflection occurs.
Net cash used in operating activities reached -$11.2M, consistent with nine-month trends driven by higher operating expenses, inventory buildup, and accounts payable reductions. Capital expenditures rose to $857K, contributing to free cash flow of -$12.0M. Liquidity was maintained through strategic actions including short-term investment sales, as management closely monitors needs and adapts strategy. They believe existing cash, equivalents, investments, operational cash flows, and potential capital raises will fund current plans and obligations for at least the next 12 months, though substantial additional expenditures are anticipated to fully realize business objectives.